Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip



    


    
    SUNNYVALE, Calif., April 30 /CNW/ -- Arrayit Corporation (OTC Bulletin
Board: ARYC), a leading manufacturer of products and services for disease
prevention, treatment and cure, announced today that it is developing a
microarray-based diagnostic test to detect the H1N1 swine flu virus.
    

    
    The Arrayit test will allow researchers and clinicians to detect the
presence of the virus in infected patients and livestock and to distinguish
the threatening mutated strain from less harmful variants in humans and swine.
Using its state-of-the-art manufacturing facility, Arrayit plans to begin mass
production of its test kits over the next several weeks. The H1N1 test kits
will be sent to the Centers for Disease Control (CDC) for validation, then
sold for emergency use by licensed clinics, laboratories and other health care
organizations worldwide.
    

    
    The 2009 swine flu outbreak has raised concerns at the CDC and the World
Health Organization (WHO). The CDC and WHO believe that the current outbreak
poses a pandemic risk because the H1N1 flu virus contains genetic elements
from both the swine and human influenza viruses, allowing direct
human-to-human transmission without the need for agricultural contact. The
dangerous 2009 strain has little immunity in the human population, resistance
to several common anti-viral drugs, and has caused serious illness and death.
    

    
    Department of Health and Human Services spokesperson said, "In the event
of an emerging pandemic, the CDC-IRR (Influenza Reagent Resource) will serve
as a source of reagents for qualified laboratories to provide additional
support. During a pandemic, laboratories will play a critical role in
detecting and confirming initial cases, characterizing viruses, monitoring the
progression of the pandemic, and selecting vaccine strains. Scientists around
the world are concerned that the influenza virus could one day mutate and
acquire the properties needed to quickly spread between people, resulting in a
pandemic."
    

    
    Arrayit's unique microarray platform allows the design, manufacture and
distribution of H1N1 chip technology quickly and inexpensively, owing to the
Company's unique and patented contact printing technology, versatile system
architecture, and broad customer base.  "Our team is able to leverage the most
sophisticated and accurate gene testing available on the market today to
rapidly and affordably bring this H1N1 flu chip test to market," said Rene
Schena, Chief Executive Officer of Arrayit Corporation.
    

    About Arrayit Corporation
    
    Arrayit Corporation, headquartered in Sunnyvale, California, leads and
empowers the genetic, research, pharmaceutical, and diagnostic communities
through the discovery, development and manufacture of proprietary life science
technologies and consumables for disease prevention, treatment and cure. It
now offers over 650 products to a customer base of more than 2,500
laboratories worldwide, including most every major university, pharmaceutical
and biotech company, major agricultural and chemical company, government
agency, national research foundation and many private sector enterprises.
Please visit www.arrayit.com for more information.
    

    Safe Harbor Statement
    
    Except for historical information contained herein, statements made in
this release that would constitute forward-looking statements may involve
certain risks and uncertainties. All forward-looking statements made in this
release are based on currently available information and the Company assumes
no responsibility to update any such forward-looking statement. The following
factors, among others, may cause actual results to differ materially from the
results suggested in the forward-looking statements. The factors include, but
are not limited to, risks that may result from changes in the Company's
business operations; our ability to keep pace with technological advances;
significant competition in the biomedical business; our relationships with key
suppliers and customers; quality and consumer acceptance of newly introduced
products; market volatility; non-availability of product; excess inventory;
price and product competition; new product introductions, the outcome of our
legal disputes; the possibility that the review of our prior filings by the
SEC may result in changes to our financial statements; and the possibility
that stockholders or regulatory authorities may initiate proceedings against
Arrayit and/or our officers and directors as a result of any restatements.
Risk factors associated with our business, including some of the facts set
forth herein, are detailed in the Company's Form 10-K for the fiscal year
ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended
March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30,
2008.
    


    

    
    Contact:
    Arrayit Corporation
    Tel: 408-744-1331
    Email: investorinfo@arrayit.com
    Web:




    




For further information:

For further information: Arrayit Corporation, +1-408-744-1331,
investorinfo@arrayit.com Web Site: http://www.arrayit.com

Organization Profile

ARRAYIT CORPORATION

More on this organization

FLU VIRUS UPDATE

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890